Development and in vitro Biological Evaluation of Polymer-Thalidomide Conjugates for Anti-Cancer Applications

Madonna Mitry – University Teacher, Faculty of Pharmacy, Ain Shams University, Cairo; Francesca Greco – Prof, University Teacher, School of Pharmacy, University of Reading,UK; Helen Osborn – Prof, University Teacher, School of Pharmacy, University of Reading,UK

Introduction:

Angiogenesis, the formation of new blood vessels, is vital for tumour metastasis and therefore a key target in cancer therapy (1). Polymer–drug conjugates show great promise by inhibiting angiogenesis, improving drug stability, transport, and bioavailability (2). Thalidomide (THA) demonstrates significant antiangiogenic and anticancer properties (3); however, its clinical use is hindered by poor aqueous solubility, limited bioavailability, and serious side effects, including teratogenicity. This project conjugates THA-amine with PEG to enhance solubility, delivery, and targeted antiangiogenic effects, facilitating safer and more effective cancer therapies.